Beactica Therapeutics Kicks Off IND-Enabling Studies for First-in-Class Glioblastoma Drug BEA-17
Beactica Therapeutics Kicks Off IND-Enabling Studies for BEA-17
Beactica Therapeutics AB, a Swedish company focusing on precision medicine, has announced an important milestone in the development of its drug candidate, BEA-17. The company has initiated IND-enabling studies that are crucial for seeking approval to begin human clinical trials. BEA-17 is designed as an oral degradation agent for the epigenetic regulators LSD1 and CoREST and is positioned to be a game-changer for glioblastoma treatment.
Glioblastoma multiforme (GBM) represents one of the most challenging cancers, often referred to as the most aggressive primary brain tumor. The standard treatment has remained largely unchanged for over two decades, leading to a grim median survival rate of about 15 months for patients. Traditional therapies, including immunotherapy, have struggled to produce meaningful results in GBM due to the tumor's immune-suppressive environment that renders the microenvironment
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.